209 related articles for article (PubMed ID: 26159874)
1. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
Klieber M; Oberacher H; Hofstaetter S; Beer B; Neururer M; Amann A; Alber H; Modak A
J Pharmacol Exp Ther; 2015 Sep; 354(3):426-30. PubMed ID: 26159874
[TBL] [Abstract][Full Text] [Related]
2. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Modak AS; Klyarytska I; Kriviy V; Tsapyak T; Rabotyagova Y
J Breath Res; 2016 Dec; 10(4):046017. PubMed ID: 27991432
[TBL] [Abstract][Full Text] [Related]
3. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
4. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
6. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
8. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
10. The clopidogrel conundrum.
Bertino JS
J Clin Pharmacol; 2014 Aug; 54(8):841-2. PubMed ID: 25044099
[No Abstract] [Full Text] [Related]
11. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
Furuta T; Kodaira C; Nishino M; Yamade M; Sugimoto M; Ikuma M; Hishida A; Watanabe H; Umemura K
Aliment Pharmacol Ther; 2009 Aug; 30(3):294-300. PubMed ID: 19459830
[TBL] [Abstract][Full Text] [Related]
12. Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Hokimoto S; Akasaka T; Tabata N; Arima Y; Tsujita K; Sakamoto K; Kaikita K; Morita K; Kumagae N; Yamamoto E; Oniki K; Nakagawa K; Ogawa H
Thromb Res; 2015 Jun; 135(6):1081-6. PubMed ID: 25891840
[TBL] [Abstract][Full Text] [Related]
13. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
15. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
16. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Siller-Matula JM; Spiel AO; Lang IM; Kreiner G; Christ G; Jilma B
Am Heart J; 2009 Jan; 157(1):148.e1-5. PubMed ID: 19081411
[TBL] [Abstract][Full Text] [Related]
17. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
[TBL] [Abstract][Full Text] [Related]
18. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
Wedemeyer RS; Blume H
Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
[TBL] [Abstract][Full Text] [Related]
20. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
